190 related articles for article (PubMed ID: 28179588)
1. TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.
Fagerholm R; Khan S; Schmidt MK; García-Closas M; Heikkilä P; Saarela J; Beesley J; Jamshidi M; Aittomäki K; Liu J; Ali HR; Andrulis IL; Beckmann MW; Behrens S; Blows FM; Brenner H; Chang-Claude J; Couch FJ; Czene K; Fasching PA; Figueroa J; Floris G; Glendon G; Guo Q; Hall P; Hallberg E; Hamann U; Holleczek B; Hooning MJ; Hopper JL; Jager A; Kabisch M; ; Keeman R; Kosma VM; Lambrechts D; Lindblom A; Mannermaa A; Margolin S; Provenzano E; Shah M; Southey MC; Dennis J; Lush M; Michailidou K; Wang Q; Bolla MK; Dunning AM; Easton DF; Pharoah PD; Chenevix-Trench G; Blomqvist C; Nevanlinna H
Oncotarget; 2017 Mar; 8(11):18381-18398. PubMed ID: 28179588
[TBL] [Abstract][Full Text] [Related]
2. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
3. The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients.
Fagerholm R; Schmidt MK; Khan S; Rafiq S; Tapper W; Aittomäki K; Greco D; Heikkinen T; Muranen TA; Fasching PA; Janni W; Weinshilboum R; Loehberg CR; Hopper JL; Southey MC; Keeman R; Lindblom A; Margolin S; Mannermaa A; Kataja V; Chenevix-Trench G; ; Lambrechts D; Wildiers H; Chang-Claude J; Seibold P; Couch FJ; Olson JE; Andrulis IL; Knight JA; García-Closas M; Figueroa J; Hooning MJ; Jager A; Shah M; Perkins BJ; Luben R; Hamann U; Kabisch M; Czene K; Hall P; Easton DF; Pharoah PD; Liu J; Eccles D; Blomqvist C; Nevanlinna H
Oncotarget; 2015 Apr; 6(10):7390-407. PubMed ID: 25823661
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
5. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
Sheng S; Xu Y; Guo Y; Yao L; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jan; 146(2):487-495. PubMed ID: 31119730
[TBL] [Abstract][Full Text] [Related]
7. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
8. Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study.
Tjader NP; Beer AJ; Ramroop J; Tai MC; Ping J; Gandhi T; Dauch C; Neuhausen SL; Ziv E; Sotelo N; Ghanekar S; Meadows O; Paredes M; Gillespie JL; Aeilts AM; Hampel H; Zheng W; Jia G; Hu Q; Wei L; Liu S; Ambrosone CB; Palmer JR; Carpten JD; Yao S; Stevens P; Ho WK; Pan JW; Fadda P; Huo D; Teo SH; McElroy JP; Toland AE
Cancer Res Commun; 2024 Jun; 4(6):1597-1608. PubMed ID: 38836758
[TBL] [Abstract][Full Text] [Related]
9. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
[TBL] [Abstract][Full Text] [Related]
11. Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance.
Arfaoui A; Douik H; Kablouti G; Chaaben AB; Handiri N; Zid Z; Ouni N; Zouiouch F; Ayari F; Mamoughli T; Bouassida J; Abazza H; Harzallaha L; Guemira F
Anticancer Res; 2015 Mar; 35(3):1763-9. PubMed ID: 25750340
[TBL] [Abstract][Full Text] [Related]
12. NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations.
Fu YP; Edvardsen H; Kaushiva A; Arhancet JP; Howe TM; Kohaar I; Porter-Gill P; Shah A; Landmark-Høyvik H; Fosså SD; Ambs S; Naume B; Børresen-Dale AL; Kristensen VN; Prokunina-Olsson L
Mol Cancer; 2010 May; 9():113. PubMed ID: 20482849
[TBL] [Abstract][Full Text] [Related]
13. Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer.
Garcia-Closas M; Kristensen V; Langerød A; Qi Y; Yeager M; Burdett L; Welch R; Lissowska J; Peplonska B; Brinton L; Gerhard DS; Gram IT; Perou CM; Børresen-Dale AL; Chanock S
Int J Cancer; 2007 Dec; 121(11):2532-8. PubMed ID: 17683073
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
[TBL] [Abstract][Full Text] [Related]
16. Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.
Jamshidi M; Schmidt MK; Dörk T; Garcia-Closas M; Heikkinen T; Cornelissen S; van den Broek AJ; Schürmann P; Meyer A; Park-Simon TW; Figueroa J; Sherman M; Lissowska J; Keong GT; Irwanto A; Laakso M; Hautaniemi S; Aittomäki K; Blomqvist C; Liu J; Nevanlinna H
Int J Cancer; 2013 May; 132(9):2044-55. PubMed ID: 23034890
[TBL] [Abstract][Full Text] [Related]
17. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies.
Guo X; Lin W; Bao J; Cai Q; Pan X; Bai M; Yuan Y; Shi J; Sun Y; Han MR; Wang J; Liu Q; Wen W; Li B; Long J; Chen J; Zheng W
Am J Hum Genet; 2018 May; 102(5):890-903. PubMed ID: 29727689
[TBL] [Abstract][Full Text] [Related]
18. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
Lei J; Rudolph A; Moysich KB; Rafiq S; Behrens S; Goode EL; Pharoah PP; Seibold P; Fasching PA; Andrulis IL; Kristensen VN; Couch FJ; Hamann U; Hooning MJ; Nevanlinna H; Eilber U; Bolla MK; Dennis J; Wang Q; Lindblom A; Mannermaa A; Lambrechts D; García-Closas M; Hall P; Chenevix-Trench G; Shah M; Luben R; Haeberle L; Ekici AB; Beckmann MW; Knight JA; Glendon G; Tchatchou S; Alnæs GI; Borresen-Dale AL; Nord S; Olson JE; Hallberg E; Vachon C; Torres D; Ulmer HU; Rüdiger T; Jager A; van Deurzen CH; Tilanus-Linthorst MM; Muranen TA; Aittomäki K; Blomqvist C; Margolin S; Kosma VM; Hartikainen JM; Kataja V; Hatse S; Wildiers H; Smeets A; Figueroa J; Chanock SJ; Lissowska J; Li J; Humphreys K; Phillips KA; ; Linn S; Cornelissen S; van den Broek SA; Kang D; Choi JY; Park SK; Yoo KY; Hsiung CN; Wu PE; Hou MF; Shen CY; Teo SH; Taib NA; Yip CH; Ho GF; Matsuo K; Ito H; Iwata H; Tajima K; Dunning AM; Benitez J; Czene K; Sucheston LE; Maishman T; Tapper WJ; Eccles D; Easton DF; Schmidt MK; Chang-Claude J
Breast Cancer Res; 2015 Feb; 17(1):18. PubMed ID: 25849327
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Skjønsberg G; Aas T; Schlichting E; Fjösne HE; Nysted A; Lillehaug JR; Lønning PE
PLoS One; 2011 Apr; 6(4):e19249. PubMed ID: 21556366
[TBL] [Abstract][Full Text] [Related]
20. Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Szkandera J; Absenger G; Dandachi N; Regitnig P; Lax S; Stotz M; Samonigg H; Renner W; Gerger A
Mol Genet Genomics; 2012 Sep; 287(9):755-64. PubMed ID: 22903472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
